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Abstract 
Background: The length of hospital stay (LOS) is important in patients admitted for acute heart failure 
(AHF) as it prolongs an unpleasant experience for the patients and adds substantially to health care 
costs.  
Methods and Results: We examined the association between LOS and baseline characteristics, 10-day 
post-discharge HF readmission, and 90-day post-discharge mortality in 1,347 patients with AHF enrolled 
in the VERITAS program. Longer LOS was associated with greater HF severity and disease burden at 
baseline; however, most of the variability of LOS could not be explained by these factors. LOS was not 
associated with readmissions during the first days after discharge. However, LOS was a significant 
predictor of 90-day mortality (Hazard ratio for 1 day increase: 1.05; 95% C.I. 1.02, 1.07, p=0.00004), 
although the association is partially explained by concurrent end organ damage and worsening heart 
failure (WHF) during the first days of admission.  
Conclusions: In patients who have been admitted for Acute HF; longer length of hospital stay 
is associated with a higher rate of short-term mortality. 
Clinical Trial Registration: VERITAS-1 and -2:Clinicaltrials.gov identifiers NCT00525707 and 
NCT00524433. https://clinicaltrials.gov/ct2/results?term=NCT00525707&Search=Search 
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Hospitalization for acute heart failure (AHF) is a major cause of morbidity and mortality and a significant 
burden on healthcare systems worldwide (1.2).   A hospitalization for AHF represents an important 
clinical event with significant consequences for the patient, including disruption of the patient’s normal 
home life, a relatively high risk of in-hospital mortality and a post-discharge period of increased re-
admission and death. The relationship between hospital length-of-stay (LOS) and post-discharge 
outcomes is of considerable interest. Although LOS has recently been suggested as a surrogate measure 
of hospital performance (3), LOS varies widely between countries and geographic regions (4-7), and 
neither studies nor guidelines provide criteria for determining the optimal LOS for patients. This absence 
of recommendation is driven by the paucity of data examining determinants of LOS and its relationship 
with outcomes after discharge. Indeed, the few studies that have examined LOS as a marker of disease 
severity reported conflicting results; on the one hand, some studies showed that longer LOS is 
associated with higher readmission rates and mortality (8), while on the other hand, regions with longer 
LOS have lower rates of short-term readmission up to day 30 (9), claimed to be mostly due to very early 
“rebound” admissions with days of discharge. Importantly, local medical practice and health system 
operation is also relevant. In some regions, a stringent system-based strategy to shorten LOS operates, 
while in others, extended hospital stays are widely accepted. These cultural disparities may have 
implications for developing strategies to prevent readmission, defining quality measures, and designing 
clinical trials in AHF. To better understand the implications of differences in LOS across different 
countries, we studied patient outcomes in hospital and up to 90 days after admission, adjusted for 
regional LOS disparities,  among the 1347 patients with AHF enrolled within 24h of admission into the 
Value of Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies (VERITAS; 
10,11).  
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Methods: 
This study is a post-hoc analysis of the VERITAS program, the design and results of which have been 
published (10).  Briefly, VERITAS-1 and -2 (Clinicaltrials.gov identifiers NCT00525707 and NCT00524433) 
were concurrent, identical, double-blind, randomized, placebo-controlled, parallel-group studies 
designed to evaluate tezosentan in the treatment of acute heart failure (AHF).  Patients > 18 years old 
who had been admitted for AHF within the previous 24 hours, with persistent dyspnea at rest and 
respiratory rate of > 24 breaths per minute, and who had received at least one dose of intravenous 
diuretic 2-24 hours prior to study drug initiation were potentially eligible for enrollment.  Eligible 
patients had to meet at least two of the following four additional criteria: 1) elevated B-type natriuretic 
peptide (BNP) or NT-pro BNP, 2) pulmonary edema on physical examination, 3) radiologic pulmonary 
congestion or edema, and 4) either left ventricular ejection fraction [LVEF] < 0.40 or wall motion index ≤ 
1.2.  For patients monitored with a pulmonary artery catheter, a cardiac index ≤ 2.5 L/min/m2 and 
pulmonary capillary wedge pressure ≥ 20 mmHg were required.  Patients were excluded if they had 
cardiogenic shock, ST segment elevation myocardial infarction, administration of a thrombolytic agent 
or ongoing ischemia, systolic blood pressure < 100 mg if not receiving a vasodilator or < 120 mmHg if 
receiving a vasodilator, hemoglobin < 10 g/dL or hematocrit < 30%, or creatinine > 2.5 mg/dL.   
After obtaining informed consent, patients were randomized to receive an intravenous infusion of either 
placebo or tezosentan, in addition to conventional care.  A total of 1435 patients were enrolled and 
treated between April 2003 and November 2005.  Medical history was taken and routine clinical 
laboratory measures assayed locally at baseline. Plasma samples were obtained immediately prior to 
study drug initiation (baseline) and stored at -20oC locally and shipped to a core laboratory for analysis 
(BioProof AG, Munich, Germany) (12). BNP and troponin I were measured using commercially-available 
ELISA kits: Peninsula Laboratories, San Carlos, USA for BNP and Labmaster, Turku, Finland for troponin I.  
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Troponin T was measured using an electrochemiluminescence immunoassay (Roche, Germany).  The 
lower limit of quantification (LLOQ) was 0.041 ng/mL for BNP, 0.01 ng/mL for troponin T and reported 
by the laboratory as not applicable for troponin I.  Because troponin I and T were highly correlated 
(r=0.87, p<0.0001) and troponin T was more often missing; only troponin I was considered.  Non-
detectable values were set to 0.5 times the LLOQ for BNP and to 0.5 times the minimum reported value 
for troponin I prior to log transformation. In-hospital WHF, which was reported through day 7, was 
defined as either the development of pulmonary edema, cardiogenic shock or other evidence of WHF, 
or failure of the patient's HF condition to improve with treatment, which required the initiation, 
reinstitution, or increase in intravenous therapy for HF or use of mechanical circulatory or ventilatory 
support or the use of hemodialysis, hemofiltration or ultrafiltration.   
 Rehospitalizations through 30 days and vital status through 180 days from baseline were collected.  
Given that the time at risk for rehospitalization in patients with longer LOS is reduced, creating possible 
bias - they spend more of the first 30 days in the hospital and hence they have no time to be readmitted 
up to day 30 when the collection of information was truncated, we examined the association between 
LOS and the risk of HF readmission during the first 10 days post-discharge in patients discharged before 
day 20. For the same considerations, 90 days post-discharge mortality was assessed and modeled (see 
below). 
Statistical Methods 
Patients were excluded if they were enrolled more than 24 hours after admission, or if missing the 
discharge date such that the LOS could not be calculated.  Each patient’s LOS was categorized as short, 
medium, or long based on the first and third tertiles within geographic region, which were 5 and 8 days 
in North America/Australia, 4 and 7 days in Israel, 8 and 14 days in Western Europe, and 8 and 11 days 
in Eastern Europe.  Baseline characteristics are presented by short, medium and long LOS. Means and 
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standard deviations, medians and first and third quartile, or geometric means for log-transformed 
variables are presented for continuous variables; groups were compared using ANOVA F-tests. Absolute 
and relative frequencies are presented for discrete variables, and were compared between groups using 
chi-square tests.   
Associations between baseline characteristics and LOS and between LOS and i) 90-day post-discharge 
mortality and ii) 10-day post-discharge HF readmission were examined using linear regression, Cox 
proportional hazards, and logistic regression models, respectively.  Because rehospitalizations were 
captured only through day 30 from baseline in VERITAS, analyses of 10-day post-discharge readmissions 
were limited to patients discharged by day 20.  Multivariable models were developed for length of stay 
(LOS), 10-day post-discharge HF readmission, and 90-day post-discharge mortality using a common 
approach.  Non-linearity of the association between each continuous predictor and the outcome was 
assessed through testing the significance of non-linear components of a restricted cubic spline 
transformation.  Plots of the predicted outcome against the value of the predictor and values of Akaike’s 
Information Criterion (AIC) and adjusted R2 were used to select transformations where needed.  Multiple 
imputation assuming multivariate normality was used for missing predictors; the proportion missing 
each covariate is given in Table 2. The final multivariable model included the predictors selected in the 
majority of the 10 imputation datasets using backwards selection at a 0.05 significance level for linear 
regression and a 0.10 significance level for Cox and logistic regression models.  Estimated effect sizes, 
confidence intervals and p-values were obtained by averaging across the imputation datasets using 
Rubin’s algorithm (13). C-statistics were computed using Harrell’s method (14, 15).  A multivariable-
adjusted estimate of the association between LOS and the outcome of interest was obtained by adding 
the LOS as a predictor in the multivariable model.  The occurrence of in-hospital WHF was then added to 
evaluate whether any association between LOS and the outcome might be explained by in-hospital 
WHF.  Days in the intensive care unit (ICU) up to day 30 were collected.  Unadjusted and multivariable-
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adjusted associations between days in the ICU and 90-day post-discharge mortality were also examined.  
All models were either adjusted or stratified by geographic region.  SAS® version 9.3 (SAS Institute, Cary, 
NC, USA) software was used for all analyses. 
Results: 
Of the 1449 patients eligible for analysis, 102 (7.0%) were excluded because they were enrolled more 
than 24 hours after admission and 10 patients because of missing LOS data.  Of the remaining 1337 
patients, 55 (4.1%) died during the initial hospitalization. The LOS by region in patients who survived to 
discharge and those who did not are presented in Table 1, and the distributions by geographic region in 
those who survived are presented in Figure 1. Patient characteristics by short, medium and long LOS 
within region are presented in Table 2. Univariable and multivariable models for LOS are presented in 
Table 3.  After multivariable adjustment, more severe dyspnea at randomization, history of diabetes 
mellitus or valvular heart disease, higher creatinine or troponin I, and lower hemoglobin (up to 14.5 
g/dL) or sodium (up to 140 mmol/L) were associated with longer LOS. Higher systolic BP (up to 145 
mmHg) was associated with shorter LOS.  
With adjustment for region, longer LOS was not associated with the risk of HF readmission from 
randomization to day 30 (OR 1.01, 95% CI 0.97-1.06, p=0.5768) in patients who were alive and 
discharged before day 30. As described above, to further examine the associations of LOS with early 
readmissions, taking into account that during the 30 days after randomization patients with longer LOS 
had less days at risk for readmission, we examined the association between LOS and the risk of HF 
readmission during the first 10 days post discharge (early “rebound” re-admissions) in the 1199 patients 
discharged before day 20.  Univariable associations between baseline characteristics and 10-day post-
discharge HF readmission are presented in supplemental Table 1. Each additional day of LOS was 
associated with an OR for 10-day readmission of 1.08 (95% CI 1.01-1.16); p=0.0189. However, after 
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multivariable adjustment for baseline characteristics, the association became non-significant [Table 4; 
OR 1.06 (0.99 -1.14); p=0.0961]. Introducing both LOS and WHF into the model diminished the 
association further [OR = 1.05 (0.97 – 1.13); p = 0.2336].  
Univariable associations with 90-day post-discharge mortality are presented in supplemental Table 2, 
and the cumulative risk by LOS category is presented in Figure 2. With adjustment only for region, longer 
LOS was associated with a higher rate of 90-day post-discharge mortality (HR for 1-day increase 1.05, 
95% CI 1.02-1.07, p=0.0004). After multivariable adjustment for baseline characteristics (Table 4), the HR 
for each additional day of LOS was reduced to 1.04 (1.01-1.07), p=0.0166. After further adjustment for 
the occurrence of in-hospital worsening heart failure (WHF), the association between LOS and 90-day 
post-discharge mortality was further reduced and became non-significant: 1.03 (1.00-1.06), p=0.0629, 
while the association between WHF and 90-day post-discharge mortality remained highly significant [HR 
1.59 (1.02-2.48), p= 0.0396].  Further adjustment for changes from baseline to 24 hours in albumin, 
creatinine, BUN, and ALT did not change the estimated HR for LOS, although further reduced statistical 
significance (1.03, 95% CI 0.99-1.06, p=0.0997). There was no interaction between LOS and tezosentan 
treatment (p=0.5482).   
Adjusted only for geographic region, days in the ICU were not significantly associated with 90-day post-
discharge mortality (HR 1.04, 95% CI 0.99-1.09, p=0.0823).  After multivariable adjustment for baseline 
characteristics, the association was nearly statistically significant (HR 1.05, 95% CI 1.00-1.11, p=0.0577); 
however, after adjustment for overall hospital LOS, association with ICU days was significantly reduced 
and became non-significant (HR 1.03, 95% CI 0.98-1.09, p=0.2717).   
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Discussion 
Hospital length of stay is increasingly used as a measure of quality of care in patients admitted for acute 
heart failure (2) both from the perspective of the patients, who perceive time in the hospital as an 
unpleasant experience and would in some cases trade years of life for less time in the hospital (16) and 
health systems for which HF admissions represent an ever-growing financial burden (17). We examined 
the predictors and associations between LOS and outcomes in the VERITAS study. First, as noted 
previously (3-6), we found that LOS varied substantially by geographical region and hence all analysis 
performed here were adjusted for geographical region. Adjusted for region, longer LOS was associated 
with some measures of more severe HF, including worse dyspnea and greater end organ dysfunction/ 
damage (elevated troponin, creatinine/ BUN), as well as co-morbidities (age, diabetes, chronic kidney 
disease, anemia)(Table 2). However, BNP was not a predictor of LOS, in either the univariable or 
multivariable analyses. The adjusted r-square (0.19) from a multivariable model suggests that most of 
the variability of LOS is not explained by heart failure severity or co-morbidities, even after adjustment 
for region. Conceivably some of this variability may be related to other factors such as hospital bed 
availability and patients’ socioeconomic status and availability of social support (18), factors that were 
not captured in the VERITAS program.  
Data on the association of LOS and outcomes is scarce. From the one hand it was  suggested (4) that 
longer LOS is associated with lower short-term (up to day 30) readmissions rates, mostly due to quick 
post discharge readmissions in the days after discharge while on the other hand a recent US based 
health care provider analysis suggested that longer LOS is associated with more early (“rebound”) and 
late readmissions and death (8)In both analysis, readmission and death were measured from 
presentation, hence  patients with shorter LOS have “more time” to be readmitted since they are 
discharged earlier and have therefore “more days” at risk given the fixed follow-up period from 
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randomization and admission, potentially biasing the analysis of the association between LOS and short-
term readmission. To clarify this issue we have undertaken an analysis in which a fixed period of days 
post discharge was examined. As the vast majority of patients had a LOS < 20 days and readmission 
information was available in VERITAS for only 30 days, we examined the rate of HF readmissions during 
the vulnerable period of the first 10 days post-discharge. This approach towards analyzing readmissions 
in early vulnerable period after discharge and their association with LOS was also supported by a recent 
analysis suggesting that post-discharge readmissions during the first few days after discharge are 
common and potentially associated with LOS, while readmissions occurring later during the post-
discharge period are not (18).  In VERITAS, longer LOS was associated with a higher (and not lower) rate 
of short-term readmission, although this association was diminished by adjustment for severity of heart 
failure at baseline, and further diminished when adjusted for the occurrence of in-hospital WHF (Table 
4).  
The univariable and multivariable associations of post discharge 90-day mortality are presented in 
supplemental table 2 and table 5. Overall baseline characteristics alone were moderately predictive of 
post discharge 90-day mortality (c-index = 0.7421). Longer LOS was associated with greater risk of 90-
day mortality. This association remained significant even after adjustment for baseline characteristics 
(Table 4). The significance of the association of LOS and 90-day post discharge mortality was reduced 
after further adjustment for changes from baseline to 24 hours in albumin, creatinine, BUN, and ALT, 
suggesting that changes in end organ function during the first day of admission may herald the adverse 
outcomes associated with longer LOS. Similarly, the association of LOS with 90-day post discharge 
mortality was significantly reduced after adjustment for in-hospital worsening heart failure (WHF). The 
association between in-patient WHF, longer LOS and adverse outcomes in VERITAS has been previously 
described (19). Indeed, in the current analysis the introduction of both in-patient WHF and LOS into the 
multivariable model diminished the association between LOS and 90-day mortality but not that of WHF 
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and 90 day mortality. This suggests that some of the risk of mortality associated with longer LOS is 
attributable to the occurrence of in-hospital WHF.  
We observed a trend towards association between ICU days and 90-days post discharge mortality, 
however this trend did not reach statistical significance, and was further reduced by adjustment for total 
in hospital LOS. As ICU days were captured in the VERITAS database only in full days it did not allow for 
granular determination of the time spent in the ICU and hence, full analysis of the contribution of ICU to 
the associations of LOS and outcomes will require further analysis in larger studies where LOS and ICU 
days are captured in more detail.   
Therefore, the analysis of the associations between LOS and 90-day mortality and LOS and 10-day 
readmission rates demonstrates concordance, i.e., longer LOS is associated with higher risk of short-
term mortality and HF readmission.  
Limitations 
This analysis is a retrospective analysis of the VERITAS program and is hence limited by the data 
collected in the study, the relatively small sample size, and especially with regard to post-discharge 
readmissions which were only collected during the first 30 days after randomization regardless of the 
discharge date. 
Conclusions: 
Longer LOS is an important outcome in AHF both from the perspective of the patient experience and 
healthcare systems. Longer LOS is only partially explained by severity of HF and co-morbidities at 
baseline. Longer LOS is associated with a higher risk of adverse outcomes post-discharge; both 10-day 
HF readmission and 90-day death, although the association with readmission was significantly reduced 
after adjustment for baseline characteristics. The association between longer LOS and mortality may be 
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heralded by worsening end organ function in the first day of admission and importantly, mediated by in-
hospital WHF. The finding that WHF is associated with longer LOS and higher mortality raises the 
possibility that therapies that prevent in-hospital WHF could improve outcomes.  
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Figure 1: Distribution of length of stay (excluding in-hospital deaths) by geographic region.  Lines on 
the box represent the 25th, 50th, and 75th percentiles, whiskers the 10th and 90th percentiles, and dots the 
5th and 95th percentiles of the distributions. 
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Figure 2: Association of length of stay (excluding in-hospital deaths) with 90-day post-discharge 
mortality.  Classification of LOS as short, medium, or long is based on tertiles of the distributions within 
geographic region. 
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Table 1: Length of stay by patient status and region 
 
 
---- Subjects who survived to discharge ---- 
(N = 1282) 
Subjects who died during initial hospital stay 
(N = 55) 
------------------------ Total ------------------------ 
(N = 1337) 
Region 
Number of 
subjects Length of stay [1] 
Number of 
subjects Length of stay [1] 
Number of 
subjects Length of stay [1] 
North America and 
Australia 
346 (27.0%) 7.8 (5.90), 6.0 (4.0 - 9.0) 8 (14.5%) 17.6 (13.88), 14.5 (6.0 - 26.0) 354 (26.5%) 8.0 (6.33), 6.0 (4.0 - 9.0) 
Israel 454 (35.4%) 6.7 (4.39), 5.0 (4.0 - 8.0) 12 (21.8%) 24.1 (30.10), 11.5 (7.5 - 31.0) 466 (34.9%) 7.2 (6.91), 5.0 (4.0 - 8.0) 
Western Europe 294 (22.9%) 12.8 (7.39), 11.0 (7.0 - 16.0) 23 (41.8%) 29.8 (43.35), 9.0 (7.0 - 31.0) 317 (23.7%) 14.0 (14.18), 11.0 (7.0 - 16.0) 
Eastern Europe 188 (14.7%) 10.9 (6.05), 9.0 (7.0 - 13.0) 12 (21.8%) 35.8 (49.20), 10.0 (5.0 - 52.0) 200 (15.0%) 12.4 (14.26), 9.0 (7.0 - 13.0) 
  
Overall 1282 (100%) 9.0 (6.33), 7.0 (5.0 - 11.0) 55 (100%) 28.1 (38.76), 10.0 (6.0 - 31.0) 1337 (100%) 9.8 (10.66), 7.0 (5.0 - 11.0) 
  
  
Notes: 
[1] Results shown are mean (standard deviation), median (25th - 75th percentile). 
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Table 2: Baseline characteristics by length of stay categories (excluding in-hospital deaths) 
 
 ----------------------------------------------------- Length of stay [1] -----------------------------------------------------  
Parameter 
n (% 
missing) Short (N = 501) Medium (N = 397) Long (N = 384) 
P-value 
[2] 
Age (years) 1282 (0.0%) 68.3 (12.67), 70.0 (60.0 - 78.0) 71.4 (12.06), 74.0 (65.0 - 81.0) 70.7 (11.93), 73.0 (64.0 - 79.0) 0.0004 
Gender: Male 1282 (0.0%) 303 (60.5%) 226 (56.9%) 228 (59.4%) 0.5544 
Race: White 1282 (0.0%) 409 (81.6%) 353 (88.9%) 343 (89.3%) 0.0008 
Time to randomization (hours) 1282 (0.0%) 10.8 (6.88), 9.3 (4.5 - 16.9) 10.8 (6.69), 8.9 (4.7 - 15.8) 11.1 (7.01), 9.3 (4.7 - 17.1) 0.6996 
BMI (kg/m2) 1215 (5.2%) 29.2 (6.45), 28.0 (24.5 - 32.5) 28.7 (5.78), 27.7 (24.9 - 31.8) 28.7 (6.48), 27.4 (24.5 - 31.2) 0.4866 
Atrial fibrillation on admission 1272 (0.8%) 124 (24.9%) 103 (26.1%) 110 (28.9%) 0.4191 
History of CHF 1272 (0.8%) 376 (75.4%) 286 (73.1%) 272 (71.2%) 0.3811 
History of COPD 1281 (0.1%) 89 (17.8%) 74 (18.6%) 82 (21.4%) 0.3767 
History of diabetes 1281 (0.1%) 218 (43.5%) 190 (47.9%) 205 (53.5%) 0.0128 
History of hyperlipidemia 1281 (0.1%) 186 (37.1%) 146 (36.8%) 125 (32.6%) 0.3313 
History of hypertension 1281 (0.1%) 393 (78.4%) 316 (79.6%) 309 (80.7%) 0.7151 
History of smoking 1281 (0.1%) 45 (9.0%) 31 (7.8%) 23 (6.0%) 0.2589 
History of IHD, PVD, stroke 1281 (0.1%) 333 (66.5%) 282 (71.0%) 275 (71.8%) 0.1679 
History of mitral/aortic valve 
disease 
1281 (0.1%) 69 (13.8%) 64 (16.1%) 73 (19.1%) 0.1055 
History of renal impairment 1272 (0.8%) 157 (31.6%) 158 (40.1%) 155 (40.7%) 0.0064 
History of liver disease 1272 (0.8%) 35 (7.0%) 30 (7.6%) 36 (9.4%) 0.4082 
Previous PCI or CABG 1281 (0.1%) 186 (37.1%) 137 (34.5%) 129 (33.7%) 0.5274 
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 ----------------------------------------------------- Length of stay [1] -----------------------------------------------------  
Parameter 
n (% 
missing) Short (N = 501) Medium (N = 397) Long (N = 384) 
P-value 
[2] 
Systolic blood pressure (mmHg) 1268 (1.1%) 130.3 (20.98), 126.5 (115.0 - 143.0) 133.0 (23.75), 129.0 (115.0 - 147.0) 131.9 (22.78), 128.0 (115.0 - 145.0) 0.1838 
Respiratory rate (breaths/min) 1266 (1.2%) 25.8 (3.79), 25.5 (24.0 - 28.0) 26.3 (4.39), 26.0 (24.0 - 28.0) 26.4 (3.93), 26.0 (24.0 - 28.0) 0.0861 
Heart rate (bpm) 1281 (0.1%) 82.9 (17.10), 81.5 (70.5 - 93.5) 83.9 (17.73), 82.5 (71.0 - 94.5) 84.1 (17.63), 82.0 (71.0 - 95.5) 0.5363 
ECG QRS interval (ms) 1273 (0.7%) 111.7 (34.88), 102.0 (80.0 - 130.0) 114.5 (34.56), 105.5 (82.0 - 139.0) 113.4 (35.29), 102.0 (86.0 - 134.0) 0.4743 
Baseline dyspnea VAS (mm) 1266 (1.2%) 60.5 (22.69), 62.0 (50.0 - 75.0) 63.4 (23.59), 68.0 (50.0 - 80.0) 64.1 (23.76), 70.0 (50.0 - 81.0) 0.0495 
Albumin (g/L) 992 (22.6%) 38.41 (5.137), 38.50 (35.00 - 42.00) 37.69 (5.138), 38.00 (34.00 - 41.00) 37.18 (5.081), 37.00 (34.00 - 40.90) 0.0067 
ALT (U/L) [3] 1113 (13.2%) 18.87, 18.39 (12.44 - 27.33) 20.50, 19.06 (12.91 - 29.20) 19.44, 18.00 (11.71 - 30.91) 0.2564 
BUN (mmol/L) [3] 1241 (3.2%) 7.80, 7.69 (5.84 - 10.00) 8.49, 8.03 (6.16 - 10.99) 8.99, 8.92 (6.48 - 12.23) <.0001 
Creatinine (umol/L) 1279 (0.2%) 110.64 (34.847), 104.31 (88.40 - 
129.06) 
117.75 (39.304), 112.13 (88.40 - 
138.34) 
121.85 (40.590), 114.92 (90.00 - 
147.31) 
<.0001 
Hemoglobin (g/dL) 1281 (0.1%) 13.55 (1.784), 13.60 (12.38 - 14.80) 13.34 (1.885), 13.30 (11.90 - 14.60) 13.08 (1.935), 12.90 (11.50 - 14.50) 0.0009 
Sodium (mmol/L) 1264 (1.4%) 138.96 (3.669), 139.00 (137.00 - 
141.00) 
138.75 (3.839), 139.00 (137.00 - 
141.00) 
138.52 (4.218), 139.00 (136.00 - 
141.00) 
0.2426 
WBC (10**9/L) 1275 (0.5%) 9.48 (3.677), 8.80 (7.00 - 11.15) 9.84 (3.657), 9.20 (7.50 - 11.40) 9.80 (3.915), 8.90 (7.20 - 11.40) 0.2780 
BNP (pg/mL) [3] 1196 (6.7%) 326.6, 378.0 (130.0 - 814.0) 389.4, 442.0 (169.0 - 990.0) 400.1, 455.0 (180.0 - 996.0) 0.0584 
Troponin I (ng/mL) [3] 1195 (6.8%) 0.0110, 0.0200 (0.0005 - 0.0780) 0.0225, 0.0420 (0.0005 - 0.1620) 0.0276, 0.0380 (0.0005 - 0.1600) <.0001 
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Notes: 
ALT, alanine aminotransferase; BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CHF, chronic 
heart failure; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; IHD, ischaemic heart disease; PCI, percutaneous coronary intervention; PVD, 
peripheral vascular disease; VAS, visual analogue scale; WBC, white blood cells. 
[1] Results shown are mean (standard deviation), median (25th - 75th percentile) for continuous variables, or prevalence (%) for dichotomous variables, unless 
otherwise noted. Numbers may vary due to missing values. 
[2] P-values from ANOVA (F-test) for continuous variables, or from Chi-squared test for dichotomous variables, unless otherwise noted. 
[3] Results shown are geometric mean, median (25th - 75th percentile). P-value from ANOVA (F-test) based on log2 transformed values. 
 
 
Table 3: Univariable and multivariable associations of baseline characteristics with length of stay (excluding in-hospital deaths) 
 
 ------- Univariable model [1] ------- ------ Multivariable model [1] ------ 
Parameter 
Mean difference for a 
change of 
Mean difference (95% 
CI) P-value 
Mean difference (95% 
CI) P-value 
Age (years) 10 0.05 (-0.23, 0.33) 0.7376   
Gender: Male Yes vs. No 0.07 (-0.58, 0.73) 0.8291   
Race: White Yes vs. No 1.44 (0.29, 2.59) 0.0141   
Time to randomization (hours) 1 0.02 (-0.02, 0.07) 0.3315   
BMI (kg/m2) 5 0.06 (-0.21, 0.34) 0.6468   
Atrial fibrillation on admission Yes vs. No 0.39 (-0.34, 1.13) 0.2927   
History of CHF Yes vs. No -0.07 (-0.81, 0.67) 0.8522   
History of COPD Yes vs. No 0.68 (-0.14, 1.50) 0.1025   
History of diabetes Yes vs. No 1.11 (0.47, 1.75) 0.0007 0.96 (0.32, 1.60) 0.0033 
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 ------- Univariable model [1] ------- ------ Multivariable model [1] ------ 
Parameter 
Mean difference for a 
change of 
Mean difference (95% 
CI) P-value 
Mean difference (95% 
CI) P-value 
History of hyperlipidemia Yes vs. No -0.42 (-1.13, 0.28) 0.2419   
History of hypertension Yes vs. No -0.11 (-0.91, 0.69) 0.7886   
History of smoking Yes vs. No -1.00 (-2.24, 0.25) 0.1159   
History of IHD, PVD, stroke Yes vs. No 0.62 (-0.09, 1.33) 0.0868   
History of mitral/aortic valve disease Yes vs. No 1.12 (0.24, 1.99) 0.0124 0.94 (0.08, 1.80) 0.0319 
History of renal impairment Yes vs. No 1.16 (0.49, 1.83) 0.0007   
History of liver disease Yes vs. No 0.96 (-0.24, 2.16) 0.1156   
Previous PCI or CABG Yes vs. No -0.04 (-0.73, 0.64) 0.8980   
Systolic blood pressure <=145 mmHg [2] 10 -0.25 (-0.49, -0.01) 0.0067 -0.25 (-0.49, -0.01) 0.0104 
Systolic blood pressure >145 mmHg [2] 10 0.54 (0.20, 0.88)  0.50 (0.16, 0.83)  
Respiratory rate (breaths/min) 5 0.36 (-0.04, 0.76) 0.0782   
Heart rate (bpm) 5 0.03 (-0.07, 0.12) 0.5978   
ECG QRS interval (ms) 10 0.04 (-0.06, 0.13) 0.4396   
Baseline dyspnea VAS (mm) 10 0.20 (0.06, 0.34) 0.0054 0.18 (0.05, 0.32) 0.0084 
Albumin (g/L) 5 -0.53 (-0.89, -0.17) 0.0041   
ALT (U/L), log2 <=4.2 [2] Doubling -0.79 (-1.54, -0.03) 0.0875   
ALT (U/L), log2 >4.2 [2] Doubling 0.44 (-0.12, 0.99)    
BUN (mmol/L), log2 <=3 [2] Doubling -0.13 (-1.12, 0.86) 0.0002   
BUN (mmol/L), log2 >3 [2] Doubling 1.53 (0.74, 2.32)    
Creatinine (umol/L) 10 0.18 (0.09, 0.26) <.0001 0.10 (0.02, 0.19) 0.0202 
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 ------- Univariable model [1] ------- ------ Multivariable model [1] ------ 
Parameter 
Mean difference for a 
change of 
Mean difference (95% 
CI) P-value 
Mean difference (95% 
CI) P-value 
Hemoglobin <=14.5 g/dL [2] 1 -0.55 (-0.80, -0.30) <.0001 -0.41 (-0.67, -0.16) 0.0063 
Hemoglobin >14.5 g/dL [2] 1 0.22 (-0.27, 0.70)  0.24 (-0.23, 0.72)  
Sodium <=140 mmol/L [2] 3 -0.59 (-0.95, -0.24) 0.0046 -0.57 (-0.92, -0.22) 0.0048 
Sodium >140 mmol/L [2] 3 0.45 (-0.19, 1.10)  0.61 (-0.03, 1.24)  
WBC (10**9/L) 5 0.25 (-0.18, 0.69) 0.2542   
BNP (ng/mL), log2 Doubling 0.15 (-0.02, 0.33) 0.0927   
Troponin I (ng/mL), log2 Doubling 0.14 (0.06, 0.22) 0.0005 0.12 (0.05, 0.20) 0.0019 
Observed adjusted R-squared    0.1935  
Bias-corrected adjusted R-squared (95% CI) [3]    0.1830 (0.1433, 
0.2228) 
 
  
Notes: 
ALT, alanine aminotransferase; BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CHF, chronic 
heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; HR, hazard ratio; IHD, ischaemic heart disease; PCI, 
percutaneous coronary intervention; PVD, peripheral vascular disease; VAS, visual analogue scale; WBC, white blood cells; WHF, worsening heart failure. 
[1] Results from linear regression model adjusted for region. 
[2] Non-linear association modeled as a linear spline. 
[3] Bootstrap estimate with 1000 resampling steps. 
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Table 4: Association of length of stay (excluding in-hospital deaths) with 10-day post-discharge HF readmission 
 
 Multivariable model [1] 
Multivariable model incl. length 
of stay [1] 
Multivariable model incl. length 
of stay and in-hospital WHF by 
day 7 [1] 
Parameter RR for a change of OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
Age (years)  1 1.03 (1.00, 1.06) 0.0306 1.03 (1.00, 1.06) 0.0369 1.03 (1.00, 1.06) 0.0401 
Systolic Blood Pressure (mmHg) 1 0.99 (0.97, 1.00) 0.0613 0.99 (0.97, 1.00) 0.0578 0.99 (0.97, 1.00) 0.0672 
Creatinine (umol/L) 1 1.01 (1.00, 1.02) 0.0049 1.01 (1.00, 1.02) 0.0095 1.01 (1.00, 1.02) 0.0145 
Sodium  (mmol/L) 1 0.93 (0.87, 1.00) 0.0356 0.93 (0.87, 1.00) 0.0379 0.93 (0.87, 1.00) 0.0456 
History of Diabetes Yes vs. No 1.78 (0.99, 3.20) 0.0533 1.76 (0.98, 3.16) 0.0584 1.75 (0.98, 3.16) 0.0608 
Length of stay (days) 1   1.06 (0.99, 1.14) 0.0961 1.05 (0.97, 1.13) 0.2336 
In-hospital WHF by day 7 Yes vs. No     1.43 (0.77, 2.67) 0.2544 
Observed C-statistic  0.7053  0.7137  0.7202  
Interaction test of length of stay with region     0.5830  0.5971 
 
Notes: 
CI, confidence interval; OR, odds ratio; WHF, worsening heart failure. 
[1] Results from logistic regression model stratified by region. 
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Table 5: Association of length of stay (excluding in-hospital deaths) with 90-day post-discharge mortality  
 
 Multivariable model [1] 
Multivariable model incl. length 
of stay [1] 
Multivariable model incl. length 
of stay and in-hospital WHF by 
day 7 [1] 
Parameter HR for a change of HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Age (years) [2] 79.00 vs. 62.00 2.88 (1.62, 5.13) 0.0005 2.89 (1.63, 5.11) 0.0014 2.87 (1.63, 5.07) 0.0011 
BMI <=30 kg/m2 [3] 5 0.69 (0.50, 0.97) 0.0971 0.69 (0.49, 0.96) 0.0920 0.69 (0.50, 0.97) 0.0950 
BMI >30 kg/m2 [3] 5 1.16 (0.77, 1.75)  1.16 (0.77, 1.74)  1.17 (0.77, 1.75)  
History of IHD, PVD, stroke Yes vs. No 1.68 (0.94, 2.98) 0.0785 1.60 (0.90, 2.86) 0.1112 1.59 (0.89, 2.84) 0.1180 
History of renal impairment Yes vs. No 1.73 (1.12, 2.66) 0.0128 1.66 (1.07, 2.55) 0.0223 1.61 (1.04, 2.48) 0.0324 
Systolic blood pressure (mmHg) 10 0.89 (0.80, 0.99) 0.0346 0.89 (0.80, 0.99) 0.0381 0.89 (0.80, 1.00) 0.0427 
Albumin (g/L) [4] 41.27 vs. 34.31 0.57 (0.39, 0.83) 0.0270 0.59 (0.40, 0.86) 0.0441 0.61 (0.42, 0.88) 0.0571 
Troponin I (ng/mL), log2 Doubling 1.04 (0.99, 1.10) 0.1149 1.04 (0.98, 1.09) 0.1780 1.03 (0.98, 1.09) 0.2270 
Length of stay (days) 1   1.04 (1.01, 1.07) 0.0166 1.03 (1.00, 1.06) 0.0629 
In-hospital WHF by day 7 Yes vs. No     1.59 (1.02, 2.48) 0.0396 
Observed C-index  0.7421  0.7527  0.7559  
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 Multivariable model [1] 
Multivariable model incl. length 
of stay [1] 
Multivariable model incl. length 
of stay and in-hospital WHF by 
day 7 [1] 
Parameter HR for a change of HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Interaction test of length of stay with region     0.1246  0.1292 
  
Notes: 
BMI, body mass index; CI, confidence interval; HR, hazard ratio; IHD, ischaemic heart disease; PVD, peripheral vascular disease; WHF, worsening heart failure. 
[1] Results from Cox proportional hazards model stratified by region. 
[2] Non-linear association modeled as a cubic polynomial. HR for the 75th vs. the 25th percentile is presented. 
[3] Non-linear association modeled as a linear spline. 
[4] Non-linear association modeled as a quadratic polynomial. HR for the 75th vs. the 25th percentile is presented. 
[5] Bootstrap estimate with 1000 resampling steps. 
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Supplemental table 1: Univariable associations between length of stay (excluding in-hospital deaths) with 10-day post-
discharge HF readmission 
 
 ------- Univariable model [1] ------- 
Parameter OR for a change of OR (95% CI) P-value 
Age (years) 1 1.03 (1.00, 1.06) 0.0298 
Male Sex Yes vs. No 0.79 (0.46, 1.38) 0.4107 
White Race Yes vs. No 1.17 (0.40, 3.39) 0.7728 
Time from randomization (hours) 1 0.99 (0.95, 1.03) 0.7051 
BMI (kg/m2) 1 0.97 (0.92, 1.02) 0.2384 
Atrial Fibrillation on Admission Yes vs. No 1.13 (0.60, 2.12) 0.7113 
History of CHF Yes vs. No 2.32 (1.02, 5.26) 0.0439 
History of COPD Yes vs. No 1.25 (0.64, 2.42) 0.5117 
History of Diabetes Yes vs. No 1.63 (0.93, 2.87) 0.0882 
History of Hyperlipidemia Yes vs. No 0.71 (0.39, 1.29) 0.2657 
History of Hypertension Yes vs. No 1.52 (0.67, 3.44) 0.3119 
History of Smoking Yes vs. No 0.45 (0.14, 1.51) 0.1959 
History of mitral/aortic Valve Disease Yes vs. No 1.27 (0.64, 2.53) 0.4910 
History of IHD, PVD, Stroke Yes vs. No 1.12 (0.59, 2.12) 0.7289 
History of Renal Impairment Yes vs. No 1.88 (1.08, 3.28) 0.0255 
History of Liver Disease Yes vs. No 0.94 (0.33, 2.71) 0.9087 
Previous PCI or CABG Yes vs. No 1.25 (0.71, 2.20) 0.4364 
Dyspnea VAS (mm) [2] 75th vs 25th (77 vs. 50) 0.82 (0.46, 1.46) 0.1021 
Systolic Blood Pressure (mmHg) 1 0.99 (0.98, 1.00) 0.0990 
Respiratory Rate (breaths/min) 1 1.03 (0.96, 1.10) 0.3785 
Heart Rate (bmp) 1 1.01 (0.99, 1.02) 0.5730 
ECG QRS Interval (ms) 1 1.00 (0.99, 1.01) 0.6921 
Albumin (g/L) 1 0.95 (0.89, 1.01) 0.0921 
Table
 ------- Univariable model [1] ------- 
Parameter OR for a change of OR (95% CI) P-value 
ALT (U/L) 1 0.99 (0.97, 1.01) 0.3172 
BUN (mmol/L), log2 Doubling 1.90 (1.32, 2.74) 0.0005 
Creatinine (umol/L) 1 1.01 (1.00, 1.02) 0.0010 
Hemoglobin (g/dL) 1 0.83 (0.71, 0.97) 0.0206 
Sodium (mmol/L) 1 0.92 (0.86, 0.98) 0.0127 
Leucocytes (109/L) 1 0.99 (0.91, 1.07) 0.7364 
BNP (ng/mL), log2 Doubling 1.10 (0.94, 1.28) 0.2260 
Troponin I (ng/mL), log2 Doubling 1.01 (0.94, 1.08) 0.8799 
Length of Stay (Days) 1 1.08 (1.01, 1.16) 0.0189 
WHF by Day 7 Yes vs. No 2.13 (1.21, 3.75) 0.0091 
 
Notes: 
ALT, alanine aminotransferase; BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; 
CABG, coronary artery bypass graft; CHF, chronic heart failure; CI, confidence interval; COPD, chronic obstructive 
pulmonary disease; ECG, electrocardiogram; IHD, ischaemic heart disease; OR, odds ratio; PCI, percutaneous 
coronary intervention; PVD, peripheral vascular disease; VAS, visual analogue 
scale; WBC, white blood cells; WHF, worsening heart failure. 
[1] Results from logistic regression model stratified by region. 
[2] Non-linear association modeled as a cubic polynomial. IR for the 75th vs. the 25th percentile is presented. 
 
 
Supplemental table 2: Univariable associations between length of stay (excluding in-hospital deaths) and 90-day post-
discharge mortality  
 
 ------- Univariable model [1] ------- 
Parameter HR for a change of HR (95% CI) P-value 
Age (years) [2] 79.00 vs. 62.00 3.81 (2.30, 6.33) 0.0186 
Gender: Male Yes vs. No 1.00 (0.66, 1.52) 0.9956 
Race: White Yes vs. No 1.46 (0.65, 3.28) 0.3606 
Time to randomization (hours) 1 1.00 (0.97, 1.03) 0.8515 
BMI <=30 kg/m2 [3] 5 0.58 (0.42, 0.79) 0.0003 
BMI >30 kg/m2 [3] 5 0.90 (0.60, 1.34)  
 ------- Univariable model [1] ------- 
Parameter HR for a change of HR (95% CI) P-value 
Atrial fibrillation on admission Yes vs. No 1.01 (0.63, 1.61) 0.9703 
History of CHF Yes vs. No 1.32 (0.80, 2.17) 0.2759 
History of COPD Yes vs. No 1.62 (1.02, 2.57) 0.0417 
History of diabetes Yes vs. No 1.11 (0.74, 1.68) 0.6162 
History of hyperlipidemia Yes vs. No 1.02 (0.65, 1.62) 0.9212 
History of hypertension Yes vs. No 0.96 (0.58, 1.59) 0.8821 
History of smoking Yes vs. No 0.55 (0.20, 1.54) 0.2573 
History of IHD, PVD, stroke Yes vs. No 2.37 (1.36, 4.16) 0.0026 
History of mitral/aortic valve disease Yes vs. No 1.59 (0.97, 2.60) 0.0636 
History of renal impairment Yes vs. No 2.22 (1.47, 3.37) 0.0002 
History of liver disease Yes vs. No 0.66 (0.26, 1.66) 0.3773 
Previous PCI or CABG Yes vs. No 1.28 (0.83, 1.96) 0.2609 
Systolic blood pressure (mmHg) 10 0.88 (0.79, 0.98) 0.0164 
Respiratory rate (breaths/min) 5 1.04 (0.82, 1.33) 0.7373 
Heart rate (bpm) 5 1.01 (0.95, 1.07) 0.7009 
ECG QRS interval (ms) 10 1.03 (0.97, 1.09) 0.3730 
Baseline dyspnea VAS (mm) 10 1.03 (0.94, 1.12) 0.5584 
Albumin (g/L) [4] 41.27 vs. 34.31 0.53 (0.36, 0.80) 0.0093 
ALT (U/L), log2 Doubling 0.93 (0.76, 1.16) 0.5325 
BUN (mmol/L), log2 Doubling 1.57 (1.20, 2.06) 0.0011 
Creatinine (umol/L) 10 1.09 (1.04, 1.14) 0.0005 
Hemoglobin (g/dL) 1 0.84 (0.75, 0.94) 0.0033 
Sodium (mmol/L) 3 0.92 (0.79, 1.07) 0.2596 
WBC (10**9/L) 5 1.21 (0.94, 1.55) 0.1417 
BNP (ng/mL), log2 Doubling 1.17 (1.03, 1.32) 0.0128 
Troponin I (ng/mL), log2 Doubling 1.08 (1.02, 1.14) 0.0053 
Length of stay (days) 1 1.05 (1.02, 1.07) 0.0004 
WHF by day 7 Yes vs. No 2.31 (1.52, 3.50) <.0001 
 ------- Univariable model [1] ------- 
Parameter HR for a change of HR (95% CI) P-value 
In-hospital WHF by day 7 Yes vs. No 2.27 (1.49, 3.45) 0.0001 
  
Notes: 
ALT, alanine aminotransferase; BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; 
CABG, coronary artery bypass graft; CHF, chronic heart failure; CI, confidence interval; COPD, chronic obstructive 
pulmonary disease; ECG, electrocardiogram; HR, hazard ratio; IHD, ischaemic heart disease; PCI, percutaneous 
coronary intervention; PVD, peripheral vascular disease; VAS, visual analogue 
scale; WBC, white blood cells; WHF, worsening heart failure. 
[1] Results from Cox proportional hazards model stratified by region. 
[2] Non-linear association modeled as a cubic polynomial. HR for the 75th vs. the 25th percentile is presented. 
[3] Non-linear association modeled as a linear spline. 
[4] Non-linear association modeled as a quadratic polynomial. HR for the 75th vs. the 25th percentile is presented. 
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